Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback